Search

Your search keyword '"Heine, Renaud"' showing total 11 results
Start Over Author "Heine, Renaud" Publication Year Range Last 10 years
11 results on '"Heine, Renaud"'

1. Sex-Based Disparities in Acute Myocardial Infarction Treatment Patterns and Outcomes in Older Adults Hospitalized Across 6 High-Income Countries: An Analysis From the International Health Systems Research Collaborative

Author

Lu, Hannah, Hatfield, Laura A., Al-Azazi, Saeed, Bakx, Pieter, Banerjee, Amitava, Burrack, Nitzan, Chen, Yu-Chin, Fu, Christina, Gordon, Michal, Heine, Renaud, Huang, Nicole, Ko, Dennis T., Lix, Lisa M., Novack, Victor, Pasea, Laura, Qiu, Feng, Stukel, Therese A., Uyl-de Groot, Carin A., Weinreb, Gabe, Landon, Bruce E., and Cram, Peter

Published
2024
Full Text
View/download PDF

3. Variation in care for patients presenting with hip fracture in six high‐income countries: A cross‐sectional cohort study.

Author

Burrack, Nitzan, Hatfield, Laura A., Bakx, Pieter, Banerjee, Amitava, Chen, Yu‐Chin, Fu, Christina, Godoy Junior, Carlos, Gordon, Michal, Heine, Renaud, Huang, Nicole, Ko, Dennis T., Lix, Lisa M., Novack, Victor, Pasea, Laura, Qiu, Feng, Stukel, Therese A., Uyl‐de Groot, Carin, Ravi, Bheeshma, Al‐Azazi, Saeed, and Weinreb, Gabe

Subjects
INTERNAL fixation in fractures, LENGTH of stay in hospitals, DEVELOPED countries, TOTAL hip replacement, CROSS-sectional method, HIP fractures, RETROSPECTIVE studies, ACQUISITION of data, HEMIARTHROPLASTY, PATIENT readmissions, COMPARATIVE studies, OSTEOPOROSIS, MEDICAL records, HOSPITAL care, DESCRIPTIVE statistics, RESEARCH funding, PATIENT care, LONGEVITY, LONGITUDINAL method, OLD age
Abstract

Background: Hip fractures are costly and common in older adults, but there is limited understanding of how treatment patterns and outcomes might differ between countries. Methods: We performed a retrospective serial cross‐sectional cohort study of adults aged ≥66 years hospitalized with hip fracture between 2011 and 2018 in the US, Canada, England, the Netherlands, Taiwan, and Israel using population‐representative administrative data. We examined mortality, hip fracture treatment approaches (total hip arthroplasty [THA], hemiarthroplasty [HA], internal fixation [IF], and nonoperative), and health system performance measures, including hospital length of stay (LOS), 30‐day readmission rates, and time‐to‐surgery. Results: The total number of hip fracture admissions between 2011 and 2018 ranged from 23,941 in Israel to 1,219,696 in the US. In 2018, 30‐day mortality varied from 3% (16% at 1 year) in Taiwan to 10% (27%) in the Netherlands. With regards to processes of care, the proportion of hip fractures treated with HA (range 23%–45%) and THA (0.2%–10%) differed widely across countries. For example, in 2018, THA was used to treat approximately 9% of patients in England and Israel but less than 1% in Taiwan. Overall, IF was the most common surgery performed in all countries (40%–60% of patients). IF was used in approximately 60% of patients in the US and Israel, but only 40% in England. In 2018, rates of nonoperative management ranged from 5% of patients in Taiwan to nearly 10% in England. Mean hospital LOS in 2018 ranged from 6.4 days (US) to 18.7 days (England). The 30‐day readmission rate in 2018 ranged from 8% (in Canada and the Netherlands) to nearly 18% in England. The mean days to surgery in 2018 ranged from 0.5 days (Israel) to 1.6 days (Canada). Conclusions: We observed substantial between‐country variation in mortality, surgical approaches, and health system performance measures. These findings underscore the need for further research to inform evidence‐based surgical approaches. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Differences in Treatment Patterns and Outcomes of Acute Myocardial Infarction for Low- and High-Income Patients in 6 Countries

Author

Landon, Bruce E., primary, Hatfield, Laura A., additional, Bakx, Pieter, additional, Banerjee, Amitava, additional, Chen, Yu-Chin, additional, Fu, Christina, additional, Gordon, Michal, additional, Heine, Renaud, additional, Huang, Nicole, additional, Ko, Dennis T., additional, Lix, Lisa M., additional, Novack, Victor, additional, Pasea, Laura, additional, Qiu, Feng, additional, Stukel, Therese A., additional, Uyl-de Groot, Carin, additional, Yan, Lin, additional, Weinreb, Gabe, additional, and Cram, Peter, additional

Published
2023
Full Text
View/download PDF

7. Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study

Author

Cram, Peter, primary, Hatfield, Laura A, additional, Bakx, Pieter, additional, Banerjee, Amitava, additional, Fu, Christina, additional, Gordon, Michal, additional, Heine, Renaud, additional, Huang, Nicole, additional, Ko, Dennis, additional, Lix, Lisa M, additional, Novack, Victor, additional, Pasea, Laura, additional, Qiu, Feng, additional, Stukel, Therese A, additional, de Groot, Carin Uyl, additional, Yan, Lin, additional, and Landon, Bruce, additional

Published
2022
Full Text
View/download PDF

9. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Author

Heine, Renaud, Thielen, Frederick W., Koopmanschap, Marc, Kersten, Marie José, Einsele, Hermann, Jaeger, Ulrich, Sonneveld, Pieter, Sierra, Jorge, Smand, Carin, Uyl-de Groot, Carin A., Universitat Autònoma de Barcelona, Health Technology Assessment (HTA), General Practice, Hematology, Clinical Haematology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and Quality of Life

Subjects
medicine.medical_specialty, Hematology, business.industry, Chronic lymphocytic leukemia, MEDLINE, Treatment options, Health technology, medicine.disease, Chimeric antigen receptor, Article, SDG 3 - Good Health and Well-being, Internal medicine, Health care, Medicine, media_common.cataloged_instance, Diseases of the blood and blood-forming organs, European union, RC633-647.5, business, Intensive care medicine, health care economics and organizations, media_common
Abstract

Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. We focused on the former France, Germany, Spain, Italy and the United Kingdom (EU-5) and the Netherlands. We conducted a review of list prices, health technology assessment reports, budget impact analysis dossiers, and published cost-effectiveness analyses. We forecasted the 10-year health expenditures on CAR T-cells for several hematological cancers in selected European Union countries. Nine cost-effectiveness studies were identified and list prices for CAR T-cell therapies ranged between 307 200 EUR and 350 000 EUR. Estimated additional costs for pre- and post-treatment were 50 359 EUR per patient, whereas the incremental costs of CAR T-cell therapy (when compared with care as usual) ranged between 276 086 EUR and 328 727 EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia in 2021, 2022, 2022, 2022, and 2025, respectively. Cumulative expenditure estimates for existing and future indications from 2019 to 2029 were on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, and incremental CAR T-cell therapy costs, respectively. CAR T-cell therapies seem to be promising treatment options for hematological cancers but the financial burden on healthcare systems in the former EU-5 and the Netherlands will contribute to a substantial rise in healthcare expenditure in the field of hematology.

Published
2021

11. Good practice physical activity programs for older adults in EU

Author

Heine, Renaud, Pavlova, Milena, Tambor, Marzena, Groot, Wim, Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care, Promovendi PHPC, TIER TA, and RS: FSE TA-TIER

Subjects
education
Abstract

Health Promotion and Prevention of Risk – Action for Seniors PROJECT POLICY BRIEF 5

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results